Stemcentrx Acquired By AbbVie For $5.8 Billion
San Francisco-based Stemcentrx, a biopharmaceuticals developer focused on cancer, has been acquired by AbbVie in a $5.8 billion deal, the two said this morning. AbbVie said it would pay $2.0 billion in cash, and the remainder in stock for Stemcentrx, and up to $4.0 billion in earn out based on milestones. Stemcentrx was venture backed by Peter Thiel, Founders Fund, Artis Ventures, Sequoia Capital, Fidelity, WTI, and others.
posted on Thursday, April 28, 2016
Related stories:
> LSI Acquired By Avago For $6.6 Billion
> PMC-Sierra Acquired By Skyworks For $2 Billion
> Sitecore Acquired By EQT For $1.14 Billion
> Atheros Acquired By Qualcomm For $3.1 Billion
> OmniVision Acquired By Private Equity Group for $1.9 Billion
silicontap.com Home